Business
A Letter from the ChromaDex Chief Executive Officer
LOS ANGELES--(BUSINESS WIRE)-- The following is issued on behalf of ChromaDex (NASDAQ: CDXC). Dear Fellow Shareholders: I want to take this opportunity to
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nThe following is issued on behalf of ChromaDex (NASDAQ: CDXC).\n\nDear Fellow Shareholders:\n\nI want to take this opportunity to provide an update on ChromaDex’s intellectual property portfolio, as well as perspective on why our business is not impacted by a recent court decision related to one of the Dartmouth patents slated to expire in 2026.\n\nLast week we learned that the U.S. Court of Appeals for the Federal Circuit affirmed a prior invalidity decision regarding the 807 Dartmouth patent.1\n\nWe believe this decision has no material impact on ChromaDex’s nicotinamide riboside (“NR”) business. In anticipation of the expiration of the Dartmouth patents, we were able to obtain a series of new, critical patents last year, which, in combination with existing IP and patents from W.R. Grace, who supplies NR to ChromaDex exclusively, we expect to protect NR for at least the next 10 years. Two of ChromaDex’s recently granted patents protect methods of making NR and various salt forms. A third recently granted patent covers a crystal form of NR methanolate chloride (“NRMCl”), while a previously granted patent in 2018, covers a crystal form of NR triacetate chloride (“NRT”). NRMCl and NRTare important intermediates in the production of the final ingredient NR Chloride (“NRCl”). In addition, W.R. Grace has two crystal forms patented for NRCl and supplies NR exclusively to ChromaDex. W.R. Grace has sued Elysium Health for infringement and is rigorously defending its crystal morphology patents globally. Collectively, these patents provide strong protection for NR. To our knowledge, no other company can produce NR, including NRCl and other salt forms of NR, at a commercial scale, without violating one or more of these patents.\n\nThe debate around the wording of the patent that we license from Dartmouth will no doubt continue. As a company that invests in R&D and intellectual property, we are concerned about the precedent this decision on the Dartmouth patent could have for patents on all isolated molecules that exist in nature but impart characteristics and uses that are not present in nature. Regardless of the final outcome, there is strong protection for NR.\n\nBut the protective moat that surrounds the Chromadex Niagen® business is not solely based on intellectual property. It is also based on a brand...